Características funcionais pulmonares e uso de broncodilatador em pacientes com fibrose cística

作者: Lucia Harumi Muramatu , Roberto Stirbulov , Wilma Carvalho Neves Forte

DOI: 10.1590/S1806-37132013000100007

关键词:

摘要: OBJECTIVE: To analyze pulmonary function parameters and pharmacodynamic response to a bronchodilator, as well the prescription of bronchodilators, in cystic fibrosis (CF) patients. METHODS: This was retrospective cohort study involving patients 6-18 years age, diagnosed with CF, followed at referral center between 2008 2010. We evaluated only those who were able perform tests (PFTs). analyzed FVC, FEV1, FEF25-75%, expressed percentages predicted values, prior after bronchodilator (pre-BD post-BD, respectively), 312 PFTs. Repeated measures ANOVA multiple comparisons used. RESULTS: The included 56 patients, divided into two groups: whose PFT results spanned 2008-2010 period (n = 37); 2009-2010 19). In group, there significant reductions post-BD FEV1 2010 (p 0.028) 2009 0.036), also case for pre-BD FEF25-75% all (2008 vs. 2009; 2010; 2010). no differences any variables studied. Among PFTs, responses occurred 24 (7.7%), which from whom had been prescribed during period. CONCLUSIONS: CF studied, loss function, indicating progressive lung disease, over time. changes greater than other variables, suggests initial involvement small airways.

参考文章(25)
Carrie Ruzal-Shapiro, CYSTIC FIBROSIS: An Overview Radiologic Clinics of North America. ,vol. 36, pp. 143- 161 ,(1998) , 10.1016/S0033-8389(05)70011-7
Ian M Balfour-Lynn, Asthma in cystic fibrosis. Journal of the Royal Society of Medicine. ,vol. 96, pp. 30- 34 ,(2003)
Clare Halfhide, Hazel J Evans, Jon Couriel, Inhaled bronchodilators for cystic fibrosis. Cochrane Database of Systematic Reviews. ,vol. 2, ,(2016) , 10.1002/14651858.CD003428.PUB3
Robin Fox, Medicine in the Millennium. Journal of the Royal Society of Medicine. ,vol. 93, pp. 37- 37 ,(2000) , 10.1177/014107680009300114
Patrick A. Flume, A role for aerosolized antibiotics Pediatric Pulmonology. ,vol. 43, ,(2008) , 10.1002/PPUL.20859
David J. Serisier, Andrew D. Coates, Simon D. Bowler, Effect of Albuterol on Maximal Exercise Capacity in Cystic Fibrosis Chest. ,vol. 131, pp. 1181- 1187 ,(2007) , 10.1378/CHEST.06-1697
Wayne J. Morgan, Steven M. Butler, Charles A. Johnson, Andrew A. Colin, Stacey C. FitzSimmons, David E. Geller, Michael W. Konstan, Michael J. Light, Harvey R. Rabin, Warren E. Regelmann, Daniel V. Schidlow, Dennis C. Stokes, Mary Ellen B. Wohl, Haley Kaplowitz, Matthew M. Wyatt, , Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatric Pulmonology. ,vol. 28, pp. 231- 241 ,(1999) , 10.1002/(SICI)1099-0496(199910)28:4<231::AID-PPUL1>3.0.CO;2-2
Steven M Rowe, John P Clancy, Advances in cystic fibrosis therapies. Current Opinion in Pediatrics. ,vol. 18, pp. 604- 613 ,(2006) , 10.1097/MOP.0B013E3280109B90